Pazopanib product-specific bioequivalence guidance

Current effective version

PDF iconAdopted guideline

Reference numberEMA/CHMP/154805/2016
Published03/01/2017
Effective from01/07/2017
KeywordsBioequivalence, generics, pazopanib
DescriptionThis document provides product-specific guidance on the demonstration of the bioequivalence of pazopanib.
Abbreviations
  • BCS Classification: Biopharmaceutics Classification System
  • AUC0-t: area under the plasma concentration curve from administration to last observed concentration at time t
  • AUC0-72: area under the plasma concentration curve from administration to last observed concentration at 72 hours
  • Cmax: maximum plasma concentration

Document history

First version
Current version

PDF iconAdopted guideline

PDF iconOverview of comments

PDF iconDraft guideline

Published: 03/01/2017

Published: 03/01/2017

Published: 02/05/2016


Related content


How useful was this page?

Add your rating